Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review

被引:25
作者
Giron Moreno, Rosa Maria [1 ]
Garcia-Clemente, Marta [2 ]
Diab-Caceres, Layla [3 ]
Martinez-Vergara, Adrian [4 ]
Martinez-Garcia, Miguel Angel [5 ]
Gomez-Punter, Rosa Mar [1 ]
机构
[1] Inst Invest Sanitaria La Princesa, Serv Neumol, Madrid 28006, Spain
[2] Hosp Univ Cent Asturias, Serv Neumol, C Ave Roma S-N, Oviedo 33011, Spain
[3] Hosp Univ 12 Octubre, Serv Neumol, Madrid 28041, Spain
[4] Hosp Univ Princesa, Serv Neumol, Madrid 28006, Spain
[5] Univ Valencia, Hosp Fe, CIBER Enfermedades Resp, Valencia 46026, Spain
来源
ANTIBIOTICS-BASEL | 2021年 / 10卷 / 05期
关键词
cystic fibrosis; treatment; inflammation; obstruction; antibiotic; CFTR modulator; genetic therapy; RNA therapy; editing gene; PSEUDOMONAS-AERUGINOSA COLONIZATION; INHALED AZTREONAM LYSINE; RECOMBINANT HUMAN DNASE; LONG-TERM AZITHROMYCIN; HIGH-DOSE IBUPROFEN; QUALITY-OF-LIFE; LUNG-DISEASE; DOUBLE-BLIND; TEZACAFTOR-IVACAFTOR; ANTIBIOTIC-TREATMENT;
D O I
10.3390/antibiotics10050486
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Cystic fibrosis (CF) is a genetic disease that causes absence or dysfunction of a protein named transmembrane conductance regulatory protein (CFTR) that works as an anion channel. As a result, the secretions of the organs where CFTR is expressed are very viscous, so their functionality is altered. The main cause of morbidity is due to the involvement of the respiratory system as a result of recurrent respiratory infections by different pathogens. In recent decades, survival has been increasing, rising by around age 50. This is due to the monitoring of patients in multidisciplinary units, early diagnosis with neonatal screening, and advances in treatments. In this chapter, we will approach the different therapies used in CF for the treatment of symptoms, obstruction, inflammation, and infection. Moreover, we will discuss specific and personalized treatments to correct the defective gene and repair the altered protein CFTR. The obstacle for personalized CF treatment is to predict the drug response of patients due to genetic complexity and heterogeneity of uncommon mutations.
引用
收藏
页数:41
相关论文
共 229 条
[91]   An update on Pseudomonas aeruginosa biofilm formation, tolerance, and dispersal [J].
Harmsen, Morten ;
Yang, Liang ;
Pamp, Suenje J. ;
Tolker-Nielsen, Tim .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2010, 59 (03) :253-268
[92]   Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus [J].
Heijerman, Harry ;
Westerman, Elsbeth ;
Conway, Steven ;
Touw, Daan ;
Doring, Gerd .
JOURNAL OF CYSTIC FIBROSIS, 2009, 8 (05) :295-315
[93]   Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial [J].
Heijerman, Harry G. M. ;
McKone, Edward F. ;
Downey, Damian G. ;
Van Braeckel, Eva ;
Rowe, Steven M. ;
Tullis, Elizabeth ;
Mall, Marcus A. ;
Welter, John J. ;
Ramsey, Bonnie W. ;
Mckee, Charlotte M. ;
Marigowda, Gautham ;
Moskowitz, Samuel M. ;
Waltz, David ;
Sosnay, Patrick R. ;
Simard, Christopher ;
Ahluwalia, Neil ;
Xuan, Fengjuan ;
Zhang, Yaohua ;
Taylor-Cousar, Jennifer L. ;
Mccoy, Karen S. .
LANCET, 2019, 394 (10212) :1940-1948
[94]   Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF [J].
Heltshe, Sonya L. ;
West, Natalie E. ;
VanDevanter, Donald R. ;
Sanders, D. B. ;
Beckett, Valeria V. ;
Flume, Patrick A. ;
Goss, Christopher H. .
CONTEMPORARY CLINICAL TRIALS, 2018, 64 :35-40
[95]  
Hewer SCL, 2020, LANCET RESP MED, V8, P975, DOI 10.1016/S2213-2600(20)30331-3
[96]   Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis [J].
Hewer, Simon C. Langton ;
Smyth, Alan R. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (04)
[97]   A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis [J].
Hodson, ME ;
Gallagher, CG ;
Govan, JRW .
EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (03) :658-664
[98]   DIFFUSE PANBRONCHIOLITIS AND CYSTIC-FIBROSIS - EAST MEETS WEST [J].
HOIBY, N .
THORAX, 1994, 49 (06) :531-532
[99]   Development and Applications of CRISPR-Cas9 for Genome Engineering [J].
Hsu, Patrick D. ;
Lander, Eric S. ;
Zhang, Feng .
CELL, 2014, 157 (06) :1262-1278
[100]   The in vitro generation of lung and airway progenitor cells from human pluripotent stem cells [J].
Huang, Sarah X. L. ;
Green, Michael D. ;
de Carvalho, Ana Toste ;
Mumau, Melanie ;
Chen, Ya-Wen ;
D'Souza, Sunita L. ;
Snoeck, Hans-Willem .
NATURE PROTOCOLS, 2015, 10 (03) :413-425